Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA)
Year: 2020
Type: article
Abstract: We first reported a phenomenon of cross-resistance to vancomycin (VCM) and daptomycin (DAP) in methicillin-resistant Staphylococcus aureus (MRSA) in 2006, but mechanisms underlying the cross-resistance remain incompletely understood. Here, we present a follow-up study aimed to investigate genetic determinants associated with the cross-resistance. Using 12 sets of paired DAP susceptible (DAP S ) and DAP non-susceptible (DAP R ) MRSA isolates from 12 patients who had DAP therapy, we (i) assessed susceptibility to DAP and VCM, (ii) compared whole-genome sequences, (iii) identified mutations associated with cross-resistance to DAP and VCM, and (iv) investigated the impact of altered gene expression and metabolic pathway relevant to the cross-resistance. We found that all 12 DAP R strains exhibiting cross-resistance to DAP and VCM carried mutations in mprF , while one DAP R strain with reduced susceptibility to only DAP carried a lacF mutation. On the other hand, among the 32 vancomycin-intermediate S. aureus (VISA) strains isolated from patients treated with VCM, five out of the 18 strains showing cross-resistance to DAP and VCM carried a mprF mutation, while 14 strains resistant to only VCM had no mprF mutation. Moreover, substitution of mprF in a DAP S strain with mutated mprF resulted in cross-resistance and vice versa. The elevated lysyl-phosphatidylglycerol (L-PG) production, increased positive bacterial surface charges and activated cell wall (CW) synthetic pathways were commonly found in both clinical isolates and laboratory-developed mutants that carry mprF mutations. We conclude that mprF mutation is responsible for the cross-resistance of MRSA to DAP and VCM, and treatment with DAP is more likely to select for mprF -mediated cross-resistance than is with VCM.
Source: Scientific Reports
Institution: Jichi Medical University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: methicillin-resistant Staphylococcus aureus, daptomycin resistance, vancomycin resistance, cross-resistance, vancomycin-intermediate Staphylococcus aureus, lysyl-phosphatidylglycerol, bacterial surface charge, cell wall biosynthesis, antibiotic resistance mechanisms, whole genome sequencing
Open Access status: gold
Estimated APC paid: $1,870
Awards: Development of bacteriophage therapy for normalisation of bacterial flora and treatment of diseases., G3334138709, Integrated understanding of the beta-lactam resistant mechanisms in mutations responsible for the beta-lactam resistance in oxacillin susceptible MRSA, G5355044374, Development of a novel antibacterial using bacteriophage and RNA targeting CRISPR system, Comprehensive transcriptome analysis of group A streptococci using the murine invasive model reveals a key gene network causing severe invasive diseases, G8302323029, Mechanism of persistent infection caused by genome rearrangement, 薬剤耐性菌に対する新規追尾型抗菌治療法の開発, Development of a chasing type antimicrobial using bacteriophage
OpenAlex ID: W3090466666
